4.6 Article

A Randomized, Controlled Trial to Investigate the Efficacy of Nebulized Poractant Alfa in Premature Babies with Respiratory Distress Syndrome

Related references

Note: Only part of the references are listed.
Article Pediatrics

Early nasal continuous positive airway pressure failure prediction in preterm infants less than 32 weeks gestational age suffering from respiratory distress syndrome

Valentina Dell'Orto et al.

Summary: Early CPAP and surfactant replacement are effective treatments for neonatal RDS, with CPAP being the first line in preterm infants. This study found that a FiO2 >= 0.23 between 180 and 240 minutes of life was strongly associated with CPAP-F in preterm infants with RDS.

PEDIATRIC PULMONOLOGY (2021)

Article Pharmacology & Pharmacy

Aerosolized Beractant in neonatal respiratory distress syndrome: A randomized fixed-dose parallel-arm phase II trial

Beena G. Sood et al.

Summary: This study investigated the feasibility, safety, and efficacy of four dosing schedules of aerosolized surfactant in preterm infants with respiratory distress syndrome. The results showed that this treatment was well tolerated, had short-term efficacy, and infants who received aerosolized surfactant were less likely to require intubation within 72 hours compared to historical controls.

PULMONARY PHARMACOLOGY & THERAPEUTICS (2021)

Review Respiratory System

Aerosol drug delivery to spontaneously-breathing preterm neonates: lessons learned

Federico Bianco et al.

Summary: The delivery of medications to preterm neonates receiving non-invasive ventilation (NIV) is a challenging scenario for aerosol medicine due to anatomical and physiological characteristics of the lungs in such infants. Factors such as low lung volumes, compliance, and irregular respiratory rates affect lung deposition. Extrinsic factors like aerosol generator choice, drug formulation, particle size distribution, NIV type, and patient interface also impact lung deposition and offer an opportunity to optimize therapy efficacy. Existing experimental and clinical data on neonatal aerosol delivery are examined, with a focus on non-invasive delivery of surfactant aerosols, providing insights and a framework for the development of inhaled drugs in this patient population.

RESPIRATORY RESEARCH (2021)

Article Respiratory System

Excipient Enhanced Growth Aerosol Surfactant Replacement Therapy in an In Vivo Rat Lung Injury Model

Franck J. Kamga Gninzeko et al.

JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY (2020)

Editorial Material Pediatrics

Aerosolized Calfactant in Infants With RDS: Surfactant Replacement 2.0?

Kirsten Glaser et al.

PEDIATRICS (2020)

Article Pediatrics

Nebulised surfactant to reduce severity of respiratory distress: a blinded, parallel, randomised controlled trial

Stefan Minocchieri et al.

ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION (2019)

Article Critical Care Medicine

Cerebral Effect of Intratracheal Aerosolized Surfactant Versus Bolus Therapy in Preterm Lambs

Carmen Rey-Santano et al.

CRITICAL CARE MEDICINE (2016)

Article Pediatrics

Incidence and Outcome of CPAP Failure in Preterm Infants

Peter A. Dargaville et al.

PEDIATRICS (2016)

Article Pediatrics

Lung Deposition of Nebulized Surfactant in Newborn Piglets

Rikard Linner et al.

NEONATOLOGY (2015)

Review Pediatrics

Aerosolized surfactants

Jan Mazela et al.

CURRENT OPINION IN PEDIATRICS (2007)

Article Pediatrics

Aerosol deposition in neonatal ventilation

JC Dubus et al.

PEDIATRIC RESEARCH (2005)